Allogene Therapeutics ALLO Accrued expenses and other liabilities
Accrued expenses and other liabilities at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.
The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Allogene Therapeutics's accrued expenses and other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Allogene Therapeutics's accrued expenses and other liabilities?
- Allogene Therapeutics (ALLO) reported accrued expenses and other liabilities of -$5.1M in Q1 2026.
- How has Allogene Therapeutics's accrued expenses and other liabilities changed year-over-year?
- Allogene Therapeutics's accrued expenses and other liabilities increased by 2.3% year-over-year, from -$5.22M to -$5.1M.